Intellia Therapeutics, Inc

XNASHealth care

Last traded price · USD

$12.34

+0.24%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:50 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $12.31
Volume: 8,788
Day's high: —
Day's low: —

In brief

Intellia Therapeutics, Inc is a health care company listed on Nasdaq, valued at about $1.73B.
Its shares closed at $12.31 on 4 Nov 2026, up 0.9% over the past year.
From India you can buy NTLA in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Intellia Therapeutics, Inc (NTLA) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole NTLA share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade NTLA options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Above its 50-day average, below its 200-day
The 4 Nov 2026 close of $12.31 was 1.1% above its 50-day average ($12.17) and 5.8% below its 200-day average ($13.07). It has closed below the 200-day for 4 sessions, since 30 Oct 2026. The 50-day average crossed below the 200-day on 11 Sep 2026, 38 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
6.5 days to cover short interest
44.4M shares were sold short at the 15 Oct 2026 settlement, 31.7% of the 140.1M shares outstanding; covering them would take 6.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Behind SPY and its sector fund XLV over 1 year
1 month: −0.5% (SPY −1.6%, XLV +13.5%). 3 months: +12.2% (SPY −0.4%, XLV +15.5%). 1 year: +0.9% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: NTLA, SPY and XLV · as of 4 Nov 2026
41% of the way up its 52-week range
Closed at $12.31 on 4 Nov 2026: 33.4% below the 52-week high of $18.48 (2 Jul 2026) and 54.8% above the low of $7.95 (21 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−0.5%

6 months−11.1%

1 year+0.9%

5 years−90.8%

Newswire

About

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Website

Notable moves

June 15, 2026
+23.20%
October 27, 2025
−42.23%
September 18, 2025
+29.81%

Newswire

About

Website

Notable moves

June 15, 2026
+23.20%
October 27, 2025
−42.23%
September 18, 2025
+29.81%

Intellia Therapeutics, Inc

XNASHealth care

Last traded price · USD

$12.34

+0.24%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:50 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $12.31
Volume: 8,788
Day's high: —
Day's low: —

In brief

Intellia Therapeutics, Inc is a health care company listed on Nasdaq, valued at about $1.73B.
Its shares closed at $12.31 on 4 Nov 2026, up 0.9% over the past year.
From India you can buy NTLA in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Intellia Therapeutics, Inc (NTLA) shares from India?

Do I need the price of a whole NTLA share to invest?

How much can I invest in US stocks in a year?

Can I trade NTLA options or futures?

Insights

Quotes run fifteen minutes behind.

Above its 50-day average, below its 200-day
The 4 Nov 2026 close of $12.31 was 1.1% above its 50-day average ($12.17) and 5.8% below its 200-day average ($13.07). It has closed below the 200-day for 4 sessions, since 30 Oct 2026. The 50-day average crossed below the 200-day on 11 Sep 2026, 38 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
6.5 days to cover short interest
44.4M shares were sold short at the 15 Oct 2026 settlement, 31.7% of the 140.1M shares outstanding; covering them would take 6.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Behind SPY and its sector fund XLV over 1 year
1 month: −0.5% (SPY −1.6%, XLV +13.5%). 3 months: +12.2% (SPY −0.4%, XLV +15.5%). 1 year: +0.9% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: NTLA, SPY and XLV · as of 4 Nov 2026
41% of the way up its 52-week range
Closed at $12.31 on 4 Nov 2026: 33.4% below the 52-week high of $18.48 (2 Jul 2026) and 54.8% above the low of $7.95 (21 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−0.5%

6 months−11.1%

1 year+0.9%

5 years−90.8%

Newswire

About

Website

Notable moves

June 15, 2026
+23.20%
October 27, 2025
−42.23%
September 18, 2025
+29.81%

Newswire

About

Website

Notable moves

June 15, 2026
+23.20%
October 27, 2025
−42.23%
September 18, 2025
+29.81%

Intellia Therapeutics, Inc

Intellia Therapeutics, Inc in brief

Above its 50-day average, below its 200-day

6.5 days to cover short interest

Behind SPY and its sector fund XLV over 1 year

41% of the way up its 52-week range

Intellia Therapeutics, Inc

Intellia Therapeutics, Inc in brief

Above its 50-day average, below its 200-day

6.5 days to cover short interest

Behind SPY and its sector fund XLV over 1 year

41% of the way up its 52-week range